Artificial intelligence workplan to guide use of AI in medicines regulation

18 December 2023 - The EMA and the Heads of Medicines Agencies have published an artificial intelligence workplan to 2028, ...

Read more →

EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

15 December 2023 - EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping ...

Read more →

CHMP issues positive opinion for Biogen’s Skyclarys (omaveloxolone), the first therapy to treat Friedreich’s ataxia, a rare neurodegenerative disease

15 December 2023 - Biogen announced the CHMP of the EMA recommended marketing authorisation for Skyclarys (omaveloxolone) for the treatment ...

Read more →

EMA recommends arpraziquantel for treatment of schistosomiasis in pre-school aged children

17 December 2023 - Astellas contributed to the development of a paediatric formulation to treat schistosomiasis as a member of ...

Read more →

Takeda receives positive CHMP opinion for Hyqvia as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy

15 December 2023 - Positive opinion based on Phase 3 ADVANCE-CIDP 1 study, which met its primary endpoint demonstrating a statistically ...

Read more →

Vertex receives CHMP positive opinion for the first CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel), for the treatment of sickle cell disease and transfusion-dependent beta thalassaemia

15 December 2023 - If approved by the European Commission, patients 12 years of age and older with severe sickle cell ...

Read more →

Apellis provides update on on-going regulatory review of pegcetacoplan for GA in the European Union

14 December 2023 - Apellis Pharmaceuticals announced today an update on the on-going review of its marketing authorisation application for ...

Read more →

First version of the Union list of critical medicines agreed to help avoid potential shortages in the EU

12 December 2023 - The European Commission, the Heads of Medicines Agencies and EMA have published the first version of the ...

Read more →

The European Commission granted marketing authorisation for Vueway (gadopiclenol) in the European Union

11 December 2023 - Vueway is a new, highly stable, macrocyclic gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging (CE-MRI): ...

Read more →

GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer

11 December 2023 - European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for ...

Read more →

EMA publishes agenda for 11-14 December 2023 CHMP agenda

11 December 2023 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

Astellas' Veoza (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause

10 December 2023 - First in class treatment option reduces number and intensity of hot flashes and night sweats ...

Read more →

European Commission approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

8 December 2023 - Conditional marketing authorisation is based on clinically meaningful response rates, duration of response, and safety from the ...

Read more →

Relaunched EMA website now live

5 December 2023 - EMA has relaunched its website: www.ema.europa.eu.  ...

Read more →

EU medicines agencies reflect on lessons learned from COVID-19

1 December 2023 - The European Medicines Regulatory Network has been at the forefront of the fight against COVID-19 with ...

Read more →